Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Insulin Icodec→

Insulin Icodec Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1188379-43-2
Molecular formula
C280H435N71O87S6
Molecular weight
6380.26 g/mol
Drug class
Once-weekly long-acting basal insulin analogueinsulin receptor agonist
Mechanism of action
Activates insulin receptors, promoting glucose uptake in skeletal muscle and adipose tissue and suppressing hepatic glucose production. The albumin-binding design extends systemic exposure and permits once-weekly administration.
Indications / reported uses
  • Once-weekly basal insulin treatment to improve glycaemic control in adults with diabetes mellitus under the applicable Awiqli product authorisation; dose conversion and monitoring are product-specific

Sources: EMA EPAR — Awiqli (insulin icodec) · US DailyMed — Awiqli · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Insulin Icodec Environmental Risk Assessment (ERA) (the Insulin Icodec ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.